Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: celeryroot.com who wrote (17411)	3/13/1998 4:00:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

It will follow Sunday.

To: celeryroot.com who wrote (17411)	3/13/1998 4:07:00 PM
From: tonyt	Read Replies (1) \| Respond to of 32384

Watch what happens Monday!

To: celeryroot.com who wrote (17411)	3/14/1998 11:47:00 AM
From: tonyt	Respond to of 32384

> any predictions for Monday >) There will probably be a 'Buffet' effect: WSJ: "WARREN BUFFETT was cautiously optimistic about equities is his annual letter to shareholders. The Berkshire Hathaway chairman said that while stocks may not be overvalued, prices are generally high."

To: celeryroot.com who wrote (17411)	3/14/1998 11:58:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Looks like LGND is continuing to expand clinical trials. I just ran across a combo using Targretin with chemo for previously untreated patients: L1069-18 PHASE 1-2 TRIAL OF TARGRETIN (LGD 1069) ORAL CAPSULES IN COMBINATION CHEMOTHERAPY IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER This is in addition to the Phase II/III maintenance trial for patients with advanced refractory disease: NSCLC-MAINTENANCE - L1069-20 PHASE 2/3 PLACEBO CONTROLLED TRIAL OF TARGRETIN CAPSULES (LGD1069) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER